Magmaris

Vascular Intervention // Coronary
Resorbable Magnesium Scaffold (RMS)

Magmaris
In a class of its own.

Download brochure        

     Confirmed clinical safety and efficacy*

     Fast Magnesium resorption time

     Better deliverability

Why Magnesium?

Magnesium alloy: Favorable mechanical properties of a robust Magnesium backbone


Robust Magnesium backbone

The mechanical strength of Magnesium is superior to polymers like PLLA.¹






Stable recoil

Magmaris has a 38% lower recoil after 1 hour.²



**Absorb, Abbott



Strong radial resistance

No significant diameter change under increasing physiological pressure.³






Rounded edges and smooth surface

The electropolished rounded edges and smooth surface of the Magmaris scaffold generate less resistance during delivery of the scaffold to the lesion.





Confirmed clinical safety and efficacy*

Confidence through evidence





All n-values represent the actual number of patients enrolled.
* Based on BIOSOLVE-II, -II/-III and -IV, for patient populations see study details.
◊ Target Lesion Failure (TLF) defined as a composite of Cardiac death, Target-Vessel Myocardial Infarction (TV-MI),
emergent Coronary Artery Bypass Grafting (eCABG), and Clinically-Driven Target Lesion Revascularization (CD-TLR).
° 0.5% scaffold thrombosis rate excluding cases with early antiplatelet or anticoagulant interruption.
^Δ 0.4% of cases without early antiplatelet or anticoagulant interruption at post procedure.






Fast resorption time

~95% of Magnesium resorbed at 12 months⁸









A more deliverable scaffold

More than 70% of physicians who have used Magmaris RMS in clinical practice have rated the device to be better than a polymeric scaffold.^10*



Better lesion crossing

Up to 40% lower lesion entry and crossing force.¹¹







Better trackability in tortuous anatomy

42% less peak force.¹²











Better pushability

73% more force transmitted from hub to tip.¹³





* Absorb, Abbott
** BioFreedom, Biosensors

Magmaris^®

Indicated for de novo coronary artery lesions.^*

1-3, 10-13. BIOTRONIK data on file; 4. Bennett J. Performance and safety of the resorbable magnesium scaffold, Magmaris in a real-world setting – Primary and secondary endpoint analysis of the full cohort (2,066 subjects) of the BIOSOLVE-IV, Presented at: TCT 2021, November 2021, Orlando, USA. ClinicalTrials.gov: NCT02817802; 5. Torzewski J. Safety and performance of Magmaris at 36-months: BIOSOLVE-IV first cohort. Presented at: EuroPCR; 2022; ClinicalTrials.gov: NCT02817802; 6. Haude M, Ince H, Kische S, et al. Sustained safety and performance of the second-generation sirolimuseluting absorbable metal scaffold: Pooled outcomes of the BIOSOLVE-II and -III trials at 3 years. Cardiovascular Revascularization Medicine. 2020. doi: 10.1016/j.carrev.2020.04.006; 7. Haude M, Toelg R , Lemos P.A et al. Sustained safety and performance of a second-generation sirolimus-eluting absorbable metal scaffold: Long-term data of the BIOSOLVE-II first-in-man trial at 5 years. Cardiovascular Revascularization Medicine. 2021. doi: 10.1016/j.carrev.2021.07.017; 8. Joner M, Ruppelt P, Zumstein P, et al. Preclinical Evaluation of Degradation Kinetics and Elemental Mapping of First and Second Generation Bioresorbable Magnesium Scaffolds. EuroIntervention. 2018 Feb 20. pii: EIJ-D-17-00708. doi: 10.4244/EIJ-D-17-00708. [Epub ahead of print]; 9. BIOSOLVE-II case, GER443-012. Courtesy of Prof. M. Haude, Rheinland Klinikum Neuss GmbH, Neuss, Germany 2015. BIOSOLVE-II and -IV based on Kaplan-Meier failure estimate analysis including censored observations. The pooled analysis of BIOSOLVE-II and -III based on frequency analysis. The 36-month data of BIOSOLVE-II and -III analysis reflecting a period up to 1’125 days at 3 years. Magmaris and BIOlute are trademarks or registered trademarks of the BIOTRONIK Group of Companies. Absorb is a trademark or registered trademark of the Abbott Group of Companies. BioFreedom is a trademark or registered trademark of Biosensors International Group, Ltd.

*Indication as per IFU.